Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy

Although the blockade of the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) pathway has become a promising treatment strategy for several types of cancers, the constitutive activation of c-Met in tumors may cause a low overall response rate to PD-1 inhibitors. Increasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Qingyun, Liang, Qiaoyan, Sun, Zujun, Yuan, Xingxing, Hou, Weihua, Wang, Yuxiong, Wang, Huijie, Yu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296967/
https://www.ncbi.nlm.nih.gov/pubmed/34350059
http://dx.doi.org/10.1080/2162402X.2021.1914954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296967/
https://www.ncbi.nlm.nih.gov/pubmed/34350059
http://dx.doi.org/10.1080/2162402X.2021.1914954

Ejemplares similares